Prostate Cancer Therapeutics Market By Drug Class - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC101436
Prostate Cancer Therapeutics Market By Drug Class (Targeted Therapy, Hormonal Therapy, Immunotherapy and Chemotherapy) - Global Industry Analysis And Forecast To 2027
Industry Outlook
The prostate cancer influences the prostate organ, the organ that delivers a portion of the liquid in semen and assumes a job in control of urine in men. The symptoms are not usually seen at the starting stage, if any symptoms occur they are like; very often urination urges, difficulty in the maintaining & commencing urination, passage of blood from the urine, and some others. The cause of this cancer is abnormality seen in the cells of prostate, these abnormal cells continue to live while the other cells tend to die. Therefore, the Prostate Cancer Therapeutics Market is anticipated to expand and has tremendous scope during the forecast period. The global Prostate Cancer Therapeutics Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Prostate Cancer Therapeutics Market is segmented based on Drug Class, the market is further divided into Targeted Therapy, Hormonal Therapy, Immunotherapy and Chemotherapy. The Hormonal Therapy section is leading the market owing to; the reduction seen in the male hormones that are responsible for the growth of this cancer. The adaption & rapid development in the immunotherapy drugs is responsible for the growth of Immunotherapy section.
Regional Insights
The North American region is dominating the global Prostate Cancer Therapeutics Market owing to increasing number of cases related to prostate cancer, high rate of death due to this cancer, more investment on the R&D for producing new targeted drugs & immunotherapies, etc.
Prostate Cancer Therapeutics Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Valeant Pharmaceuticals North America LLC (Dendreon Corporation)
- Johnson & Johnson
- AstraZeneca
- Astella Inc.
- Bayer AG
- Sanofi
- Ipsen
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Prostate Cancer Therapeutics Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
o Targeted Therapy
o Hormonal Therapy
o Immunotherapy
o Chemotherapy
o Prostate Cancer Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Prostate Cancer Therapeutics Market, By Country
o U.S. Prostate Cancer Therapeutics Market
o Canada Prostate Cancer Therapeutics Market
o Mexico Prostate Cancer Therapeutics Market
o Europe
§ Europe Prostate Cancer Therapeutics Market, By Country
o Germany Prostate Cancer Therapeutics Market
o UK Prostate Cancer Therapeutics Market
o France Prostate Cancer Therapeutics Market
o Russia Prostate Cancer Therapeutics Market
o Italy Prostate Cancer Therapeutics Market
o Rest of Europe Prostate Cancer Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Prostate Cancer Therapeutics Market, By Country
o China Prostate Cancer Therapeutics Market
o Japan Prostate Cancer Therapeutics Market
o South Korea Prostate Cancer Therapeutics Market
o India Prostate Cancer Therapeutics Market
o Southeast Asia Prostate Cancer Therapeutics Market
o Rest of Asia-Pacific Prostate Cancer Therapeutics Market
o South America
§ South America Prostate Cancer Therapeutics Market, By Country
o Brazil Prostate Cancer Therapeutics Market
o Argentina Prostate Cancer Therapeutics Market
o Columbia Prostate Cancer Therapeutics Market
o Rest of South America Prostate Cancer Therapeutics Market
o Middle East and Africa
§ Middle East and Africa Prostate Cancer Therapeutics Market, By Country
o Saudi Arabia Prostate Cancer Therapeutics Market
o UAE Prostate Cancer Therapeutics Market
o Egypt Prostate Cancer Therapeutics Market
o Nigeria Prostate Cancer Therapeutics Market
o South Africa Prostate Cancer Therapeutics Market
o Rest of MEA Prostate Cancer Therapeutics Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Prostate Cancer Therapeutics Market, By Drug Class
5.1. Introduction
5.2. Global Prostate Cancer Therapeutics Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Prostate Cancer Therapeutics Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Targeted Therapy
5.3.1. Global Targeted Therapy Revenue and Growth Rate (2017-2027)
5.4. Hormonal Therapy
5.4.1. Global Hormonal Therapy Revenue and Growth Rate (2017-2027)
5.5. Immunotherapy
5.5.1. Global Immunotherapy Revenue and Growth Rate (2017-2027)
5.6. Chemotherapy
5.6.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
6. Prostate Cancer Therapeutics Market, By Region
6.1. Introduction
6.2. Global Prostate Cancer Therapeutics Revenue and Market Share by Regions
6.2.1. Global Prostate Cancer Therapeutics Revenue by Regions (2017-2027)
6.3. North America Prostate Cancer Therapeutics by Countries
6.3.1. North America Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2027)
6.3.2. North America Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Prostate Cancer Therapeutics by Countries
6.4.1. Europe Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2027)
6.4.2. Europe Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Prostate Cancer Therapeutics by Countries
6.5.1. Asia-Pacific Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Prostate Cancer Therapeutics by Countries
6.6.1. South America Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2027)
6.6.2. South America Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Prostate Cancer Therapeutics by Countries
6.7.1. Middle East and Africa Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Valeant Pharmaceuticals North America LLC (Dendreon Corporation)
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Revenue and Market Share
7.2. Johnson & Johnson
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Revenue and Market Share
7.3. AstraZeneca
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Revenue and Market Share
7.4. Astella Inc.
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Revenue and Market Share
7.5. Bayer AG
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Revenue and Market Share
7.6. Sanofi
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Revenue and Market Share
7.7. Ipsen
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Revenue and Market Share
8. Global Prostate Cancer Therapeutics Market Competition, by Manufacturer
8.1. Global Prostate Cancer Therapeutics Revenue and Market Share by Manufacturer (2017-2017)
8.2. Global Prostate Cancer Therapeutics Price By Region (2017-2017)
8.3. Top 5 Prostate Cancer Therapeutics Manufacturer Market Share
8.4. Market Competition Trend
9. Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.1. Global Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Prostate Cancer Therapeutics Market Forecast by Regions (2017-2027)
9.2.1. North America Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.1.1. United States Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.1.2. Canada Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.1.3. Mexico Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2. Europe Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.1. Germany Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.2. France Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.3. UK Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.4. Russia Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.5. Italy Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3. Asia-Pacific Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.1. China Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.2. Japan Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.3. Korea Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.4. India Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.4. South America Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.4.1. Brazil Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.4.2. Argentina Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.4.3. Columbia Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.4.4. Rest of South America Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5. Middle East and Africa Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.3. Egypt Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.4. Nigeria Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.5. South Africa Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.6. Turkey Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Prostate Cancer Therapeutics Market Forecast (2017-2027)
9.3. Prostate Cancer Therapeutics Market Forecast by Drug Class (2017-2027)
9.3.1. Prostate Cancer Therapeutics Forecast by Drug Class (2017-2027)
9.3.2. Prostate Cancer Therapeutics Market Share Forecast by Drug Class (2017-2027)
List of Tables
10. List of Tables and Figures
Figure United States Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Prostate Cancer Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Prostate Cancer Therapeutics Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Targeted Therapy Revenue and Growth Rate (2017-2018)
Figure Global Hormonal Therapy Revenue and Growth Rate (2017-2018)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Table Global Prostate Cancer Therapeutics Revenue by Regions (2017-2018)
Figure North America Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure North America Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Prostate Cancer Therapeutics by Countries (2017-2018)
Figure North America Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure United States Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Canada Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Mexico Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Europe Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Prostate Cancer Therapeutics by Countries (2017-2018)
Figure Europe Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Germany Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure France Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure UK Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Russia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Italy Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Prostate Cancer Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure China Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Japan Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Korea Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure India Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure South America Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Prostate Cancer Therapeutics by Countries (2017-2018)
Figure South America Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Brazil Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Argentina Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Columbia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Prostate Cancer Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Prostate Cancer Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Prostate Cancer Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Egypt Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Nigeria Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure South Africa Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Turkey Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Prostate Cancer Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Valeant Pharmaceuticals North America LLC (Dendreon Corporation) Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Johnson & Johnson Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AstraZeneca Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Astella Inc. Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer AG Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ipsen Prostate Cancer Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Prostate Cancer Therapeutics Market Share by Manufacturer
Figure Global Prostate Cancer Therapeutics Revenue and Market Share by Manufacturer
Table Global Prostate Cancer Therapeutics Price by Region (2017-2017)
Figure Top 5 Prostate Cancer Therapeutics Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Prostate Cancer Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Prostate Cancer Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure United States Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Canada Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Mexico Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Europe Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Germany Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure France Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure UK Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Russia Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Italy Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure China Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Japan Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Korea Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure India Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure South America Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Brazil Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Argentina Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Columbia Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Egypt Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Nigeria Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure South Africa Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Turkey Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Prostate Cancer Therapeutics Market Forecast (2018-2025)
Figure Global Prostate Cancer Therapeutics Forecast by Drug Class (2018-2025)
Figure Global Prostate Cancer Therapeutics Market Share Forecast by Drug Class (2018-2025)
Figure Global Prostate Cancer Therapeutics Forecast by Drug Class (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|